Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · Real-Time Price · USD
0.6310
-0.0102 (-1.59%)
At close: Oct 2, 2026, 4:00 PM EDT
0.6499
+0.0189 (3.00%)
After-hours: Oct 2, 2026, 7:57 PM EDT
Oncolytics Biotech Employees
Oncolytics Biotech had 29 employees as of December 31, 2025. The number of employees increased by 1 or 3.57% compared to the previous year.
Employees
29
Change (1Y)
1
Growth (1Y)
3.57%
Revenue / Employee
n/a
Profits / Employee
-$1,291,586
Market Cap
80.46M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 29 | 1 | 3.57% |
| Dec 31, 2024 | 28 | -1 | -3.45% |
| Dec 31, 2022 | 29 | 3 | 11.54% |
| Dec 31, 2021 | 26 | 1 | 4.00% |
| Dec 31, 2020 | 25 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Adicet Bio | 102 |
| Pelthos Therapeutics | 92 |
| Verrica Pharmaceuticals | 76 |
| ImmuCell | 73 |
| Connect Biopharma Holdings | 64 |
| iBio, Inc. | 23 |
| Gain Therapeutics | 21 |
| Atara Biotherapeutics | 10 |
ONCY News
- 3 days ago - Oncolytics announces publication of data on pelareorep in liver cancer - TheFly
- 3 days ago - Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy - GlobeNewsWire
- 4 days ago - Oncolytics reports accelerating enrollment in REO 033 study - TheFly
- 4 days ago - Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study - GlobeNewsWire
- 22 days ago - Oncolytics reports pelareorep preclinical results - TheFly
- 22 days ago - Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer - GlobeNewsWire
- 6 weeks ago - Oncolytics price target lowered to $5 from $10 at H.C. Wainwright - TheFly
- 6 weeks ago - Oncolytics aligns with FDA on path for REO 033 expansion study - TheFly